Jackie Hunter, CEO BenevolentBio is giving a talk at Web Summit 2017 on how Artificial Intelligence is revolutionising the methods in drug development.
"If you come into my world, in biomedicine, everyday thousands of papers are uploaded in portal like PubMed, new genome sequences, new biomarkers, new clinical trial data, we are drowning in data [...] Artificial intelligence could be the solution for a broken drug discovery model."
Jackie Hunter PhD CBE FBPharmacolS FMedScHeld senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners and joined BenevolentAI as a Director in 2016. Jackie has vast academic and business experience in the biomedical and pharmaceutical sectors. She directs the application of BenevolentAI’s technology for clinical development and gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.